Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 254

Sort by

Sort Order Select

Journal Articles

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

Matthew J. Frigault, Sarah Nikiforow, Michael K. Mansour, Zhen-Huan Hu, Mary M. Horowitz, Marcie L. Riches, Peiman Hematti, Cameron J. Turtle, Mei-Jie Zhang, Miguel-Angel Perales, Marcelo C. Pasquini

Blood (2020) 136 (1): 137–139.

https://doi.org/10.1182/blood.2020006216

Published: 2020

Journal Articles

Decline in Insulin-like Growth Factor-1 (IGF1) from Aged Mesenchymal Stromal Cells Is a Targetable Mechanism to Rescue Hematopoietic Stem Cell Aging

Kira Young, PhD, Elizabeth Eudy, BS, Matthew Loberg, BA, Rebecca Bell, BA, Jennifer Trowbridge, PhD

Blood (2019) 134 (Supplement_1): 526.

https://doi.org/10.1182/blood-2019-124534

Published: 2019

Journal Articles

Risk of Serious Infections with Carfilzomib in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Somedeb Ball, MD, Tapas Ranjan Behera, Sariya Wongsaengsak, MD, Nuvneet Khandelwal, MD, Rajshekhar Chakraborty, MD

Blood (2019) 134 (Supplement_1): 1841.

https://doi.org/10.1182/blood-2019-125464

Published: 2019

Journal Articles

Immune Reconstitution and Long-Term Outcomes Following Allo-HCT with TLI-ATG and Post-Transplant Rituximab

Vanessa E Kennedy, MD, Sally Arai, MD, David B Miklos, MD PhD, Fang Wu

Blood (2019) 134 (Supplement_1): 1996.

https://doi.org/10.1182/blood-2019-129804

Published: 2019

Journal Articles

Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family

Thomas W. LeBlanc, MDMA,MHS, Roland B. Walter, MD PhD MS, Loriana Hernandez-Aldama, Kate Sully, PhD, Timothy J Bell, MHA, Chloe Johnson, Francois Peloquin, MSc, Adam Gater, Verna L Welch, PhD MPH, Louise O'Hara, Ryan Hohman, Diana Merino, Nigel H. Russell, MD, Neil Horikoshi, Dawn Maze, MDFRCPC,MSc

Blood (2019) 134 (Supplement_1): 3498.

https://doi.org/10.1182/blood-2019-124660

Published: 2019

Journal Articles

Rituximab for Preventing Delayed Hemolytic Transfusion Reaction (DHTR) in Sickle CELL Adult Patients: Outcome of Transfusion and SIDE Effects in 58 CASES

Fabian Zanchetta-Balint, France Pirenne, MD PhD, Marc Michel, Armand Mekontso-Dessap, MD PhD, Matthieu Mahevas, MD, Constance Guillaud, MD, Keyvan Razazi, MD, Elena Foïs, MD, Frédéric Galactéros, MD PhD, Pablo Bartolucci, MD PhD, Anoosha Habibi

Blood (2019) 134 (Supplement_1): 3687.

https://doi.org/10.1182/blood-2019-130874

Published: 2019

Journal Articles

Quantification of Humoral Immune Response to Influenza Vaccination in MDS

Pankit Vachhani, MD, Kyle Wiatrowski, Pragya Srivastava, PhD, Lisa King, Jody Manischewitz, Hana Golding, Heather L Bashaw, BA, Ava R. Dimitroff, Amanda Przespolewski, DO, James E. Thompson, MD, Swapna Thota, MD, Eunice S. Wang, MD, Michael J. Nemeth, PhD, Elizabeth A. Griffiths, MD

Blood (2019) 134 (Supplement_1): 4756.

https://doi.org/10.1182/blood-2019-126176

Published: 2019

Journal Articles

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208)

Madan Jagasia, MBBS, MS, MMHC, Amandeep Salhotra, MD, Carlos R. Bachier, MD, Behyar Zoghi, MD, PhD, FACP, Aleksandr Lazaryan, MDPhDMPH, Daniel J. Weisdorf, MD, James Essell, MD, Laurie S. Green, MD, Olivier Schueller, PhD, Lindy Huang, Zhongming Yang, PhD, David Eiznhamer, PhD, Sanjay K. Aggarwal, MD, Bruce R. Blazar, MD, Stephanie J. Lee, MD MPH

Blood (2019) 134 (Supplement_1): 872.

https://doi.org/10.1182/blood-2019-125986

Published: 2019

Journal Articles

Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Anna B. Halpern, MD, Nicholas P Howard, Megan Othus, PhD, Paul C. Hendrie, MD PhD, Nikita Vashi Baclig, MD MPH, Sarah A Buckley, MD, Mary-Elizabeth M. Percival, MD, Pamela S. Becker, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Terry B. Gernsheimer, MD, Sioban B. Keel, MD, Johnnie Orozco, MD, Ryan D. Cassaday, MD, Andrei R Shustov, MD, Garrett Hartley, Verna L Welch, PhD MPH, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 1317.

https://doi.org/10.1182/blood-2019-124586

Published: 2019

Journal Articles

Comparative Analysis of Patterns of Infectious Complications of Outpatient Vs. Inpatient Care Following Intensive Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasms

Anna B. Halpern, MD, Nicholas P Howard, Megan Othus, PhD, Paul C. Hendrie, MD PhD, Nikita Vashi Baclig, MD MPH, Sarah A Buckley, MD, Mary-Elizabeth M. Percival, MD, Pamela S. Becker, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Terry B. Gernsheimer, MD, Sioban Keel, MD, Johnnie Orozco, MD, Ryan D. Cassaday, MD, Andrei R Shustov, MD, Garrett Hartley, Verna L Welch, PhD MPH, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 1323.

https://doi.org/10.1182/blood-2019-123605

Published: 2019

Journal Articles

Standard Definitions of Pneumococcal Immunity May Not Accurately Predict Protection in Adults with Sickle Cell Disease

Tara M. Robinson, MD PhD, Sophie M. Lanzkron, MD

Blood (2019) 134 (Supplement_1): 1014.

https://doi.org/10.1182/blood-2019-126056

Published: 2019

Journal Articles

Antibody Dependent Enhancement of Infections after High Dose Chemotherapy

Jens Magnus Bernth-Jensen, MD, Bjarne Kuno Møller, MD, Steffen Thiel, PhD, Anette Tarp Hansen, MD PhD

Blood (2019) 134 (Supplement_1): 1047.

https://doi.org/10.1182/blood-2019-122236

Published: 2019

Journal Articles

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

Faouzi Djebbari, Fotios Panitsas, Catherine Prodger, Fearn Davies, Kieran Burton, Akhil Khera, Grant Vallance, B.Sc., PhD, Sally Moore, Jaimal Kothari, Andy Peniket, MD, Karthik Ramasamy, MD PhD

Blood (2019) 134 (Supplement_1): 4768.

https://doi.org/10.1182/blood-2019-128139

Published: 2019

Journal Articles

Updated Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Infection and Pneumonia in Patients with Multiple Myeloma Treated with Daratumumab

Thura Win Htut, MBBS, MRCP, Aung M Tun, MD, Anita Sultan, MD, Myint Aung Win, MDMBBS, Sriman Swarup, MDMBBS, Ei Moe Phyu, MD, Pwint Phyu Hlaing, MD, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Donald P. Quick, MD, Nicholas D'Cunha, MD, Lukman Tijani, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 4771.

https://doi.org/10.1182/blood-2019-123169

Published: 2019

Journal Articles

Genetically Engineered Hematopoietic Progenitors Derived from Human Induced Pluripotent Stem Cells Achieve the Feeder-Free and Robust Production of Neutrophils with the Functional Capacity In Vivo

Masashi Miyauchi, Yusuke ITO, MD, Fumio Nakahara, MD PhD, Fumi Nakamura, MD PhD, Yuki Iwasaki, Taiki Kawagoshi, Yuki Kagoya, MD PhD, Shunya Arai, MD PhD, Mineo Kurokawa, MD PhD

Blood (2019) 134 (Supplement_1): 720.

https://doi.org/10.1182/blood-2019-126348

Published: 2019

Journal Articles

Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies

Julie Kanter, MD, Darla K Liles, MD, Kim Smith-Whitley, MD, Clark Brown, MD PhD, Abdullah Kutlar, MD, Brian Elliott, Amit Shah, Jeremie Lincy, Susan Poggio, Kenneth I. Ataga, MBBS

Blood (2019) 134 (Supplement_1): 991.

https://doi.org/10.1182/blood-2019-123965

Published: 2019

Journal Articles

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Adrian C. Newland, Blanca Sánchez-González, László Rejtő, Miklos Egyed, Nataliya Romanyuk, Marie Godar, Katrien Verschueren, Domenica Gandini, Peter Ulrichts, Jon Beauchamp, Torsten Dreier, E. Sally Ward, Marc Michel, Howard A. Liebman, Hans De Haard, Nicolas Leupin, David J. Kuter

Blood (2019) 134 (Supplement_1): 895.

https://doi.org/10.1182/blood-2019-128022

Published: 2019

Journal Articles

Inducible Expression of Mutant ELANE Correlates with Disruption of Differentiation Program, but Not the Unfolded Protein Response

Bhavuk Garg, PhD, Hrishikesh M Mehta, PhD, Ralph Kamel, Marshall S. Horwitz, MD PhD, Seth J. Corey, MD

Blood (2019) 134 (Supplement_1): 103.

https://doi.org/10.1182/blood-2019-127409

Published: 2019

Journal Articles

PreVent-ACaLL Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping

Caspar Da Cunha-Bang, MD PhD, Rudy Agius, Arnon P. Kater, Mark-David Levin, MD PhD, Anders Österborg, MD PhD, Mattias Mattsson, MD, Carsten Utoft Niemann, MD PhD

Blood (2019) 134 (Supplement_1): 4304.

https://doi.org/10.1182/blood-2019-121907

Published: 2019

Journal Articles

Discovery of DWP213388, a Potent ITK and BTK Selective Dual Inhibitor with Excellent Efficacy and Safety, for Treating Gvhd

Deokki Eom, BS, Jae Hun Jung, Eun Kyung KIM, PhD, Wolyoung Kim, Qingri Li, Jaehyun Jung, Sohee Im, Yong Dae Shin, Hyaejung Hyun, Joon Seok Park

Blood (2019) 134 (Supplement_1): 4426.

https://doi.org/10.1182/blood-2019-126839

Published: 2019

NARROW

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

Decline in Insulin-like Growth Factor-1 (IGF1) from Aged Mesenchymal Stromal Cells Is a Targetable Mechanism to Rescue Hematopoietic Stem Cell Aging

Risk of Serious Infections with Carfilzomib in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Immune Reconstitution and Long-Term Outcomes Following Allo-HCT with TLI-ATG and Post-Transplant Rituximab

Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family

Rituximab for Preventing Delayed Hemolytic Transfusion Reaction (DHTR) in Sickle CELL Adult Patients: Outcome of Transfusion and SIDE Effects in 58 CASES

Quantification of Humoral Immune Response to Influenza Vaccination in MDS

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208)

Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Comparative Analysis of Patterns of Infectious Complications of Outpatient Vs. Inpatient Care Following Intensive Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasms

Standard Definitions of Pneumococcal Immunity May Not Accurately Predict Protection in Adults with Sickle Cell Disease

Antibody Dependent Enhancement of Infections after High Dose Chemotherapy

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

Updated Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Infection and Pneumonia in Patients with Multiple Myeloma Treated with Daratumumab

Genetically Engineered Hematopoietic Progenitors Derived from Human Induced Pluripotent Stem Cells Achieve the Feeder-Free and Robust Production of Neutrophils with the Functional Capacity In Vivo

Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Inducible Expression of Mutant ELANE Correlates with Disruption of Differentiation Program, but Not the Unfolded Protein Response

PreVent-ACaLL Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping

Discovery of DWP213388, a Potent ITK and BTK Selective Dual Inhibitor with Excellent Efficacy and Safety, for Treating Gvhd

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only